📋[Comment] Targeted advertising in generative artificial inteOtherMedium Concern

[Comment] Targeted advertising in generative artificial intelligence chatbots: a new public health risk

The LancetApril 27, 20261 min read

This is an editorial summary of research originally reported by The Lancet. ProductSafer does not claim ownership of the underlying research. All intellectual property belongs to the original publishers.

OpenAI has announced plans to introduce advertising within free and low-cost versions of ChatGPT, alongside voluntary safeguards including separation of advertisements from responses, privacy protections, exclusion of users younger than 18 years, and limits on advertising around sensitive topics such as health.1,2 This shift was predictable, given the substantial losses associated with capital-intensive artificial intelligence (AI) models and the proven profitability of targeted advertising on d

This summary is based on reporting by The Lancet. For the complete article and full research details, see the original report linked below.

Read the full report at the original source

The Lancet

Was this finding useful?

More findings in Other 📋

Rectal cancer: Millennials with family history📋 OtherMedium ConcernNEW

Rectal cancer: Millennials with family history may need screening at 35 - NewsNation

Rectal cancer: Millennials with family history may need screening at 35 NewsNation Rectal cancer deaths rising rapidly among millennials: 'It's a medical crisis.' NBC News Young Adult Bowel Cancer Deaths Concentrated in One Group, Study Finds ScienceAlert Rectal Cancer 'Crisis'; Smells Like Cancer; Flushing Away Clues to Colon Cancer MedPage Today The Cancer Crisis We Can See Coming And Have the Tools to Change MedCity News

Google Health News

Apr 27, 2026

[Articles] Efficacy and safety of oral semaglutide 14 mg (fl📋 OtherMedium ConcernNEW

[Articles] Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease. Safety and tolerability of semaglutide in early Alzheimer's disease is consistent with studies in other indications.

The Lancet

Apr 27, 2026

[Comment] Learning from swine influenza, Ebola virus disease📋 OtherMedium ConcernNEW

[Comment] Learning from swine influenza, Ebola virus disease, and Legionnaires' disease in 1976

50 years ago during a US election year marked by post-Vietnam war disillusionment, post-Watergate cynicism, and bicentennial optimism, three new infectious threats stress-tested the US public health system. Throughout 1976, a series of challenges emerged: an outbreak of swine influenza A (H1N1) among US troops in New Jersey, NJ, USA; a lethal pneumonia cluster tied to the American Legion Convention in Philadelphia, PA, USA; and an unexplained haemorrhagic fever outbreak in Africa. Although the p

The Lancet

Apr 27, 2026

Back to all findings

[Comment] Targeted advertising in generative artificial intelligence chatbots: a new public health risk

More findings in Other 📋

Rectal cancer: Millennials with family history may need screening at 35 - NewsNation

[Articles] Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

[Comment] Learning from swine influenza, Ebola virus disease, and Legionnaires' disease in 1976

Never miss a finding